Search Result

Results for "

177Lu

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (1) Biochemical Assay Reagents (2) Carbonic Anhydrase (1) CXCR (2) Drug Intermediate (1) Drug-Linker Conjugates for ADC (1) FAP (8) PSMA (5) Radionuclide-Drug Conjugates (RDCs) (11) Somatostatin Receptor (2)
By Research Areas:	Cancer (23) Inflammation/Immunology (1)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-NP177

Dog hair and epithelia extract	Biochemical Assay Reagents	Inflammation/Immunology
Dog hair and epithelia extract is an allergen extracted from dog hair and epithelia samples, which can be used as an allergen for detection in allergic reactions .

HY-139551

Guraxetan	Drug Intermediate	Cancer
Guraxetan can be used for the synthesis of antineoplastic lutetium (177Lu) zadavotide Guraxetan .

HY-146180

FSDD0I	FAP	Cancer
FSDD0I is an albumin-binding fibroblast activation protein (FAP) ligand. FSDD0I can be labeled with ⁶⁸Ga and ¹⁷⁷Lu for single photon emission computed tomography (SPECT) imaging .

HY-146181

FSDD1I	FAP	Cancer
FSDD1I is an albumin-binding fibroblast activation protein (FAP) ligand. FSDD1I can be labeled with ⁶⁸Ga and ¹⁷⁷Lu for single photon emission computed tomography (SPECT) imaging .

HY-146182

FSDD3I	FAP	Cancer
FSDD3I is an albumin-binding fibroblast activation protein (FAP) ligand. FSDD3I can be labeled with ⁶⁸Ga and ¹⁷⁷Lu for single photon emission computed tomography (SPECT) imaging .

HY-174421

FAPI-JNU	FAP	Cancer
FAPI-JNU is a molecule targeting fibroblast activation protein (FAP). FAPI-JNU specifically binds to FAP highly expressed in the tumor microenvironment, and uses radionuclides [ ⁶⁸Ga]Ga or [ ¹⁷⁷Lu]Lu to achieve tumor imaging diagnosis. [177Lu]Lu−FAPI−JNU can effectively target and inhibit tumor growth in tumor-bearing mice. FAPI-JNU is promising for research of FAP-positive tumors (such as various solid tumors) .

HY-172150

XH02	Biochemical Assay Reagents	Cancer
XH02 is a compound based on L6 modification. XH02 ( ¹⁷⁷Lu labeled) displays exceptional tumor growth inhibition in BxPC-3 tumors .

HY-173116

DOTA-XYIMSR-01	Carbonic Anhydrase	Cancer
DOTA-XYIMSR-01 is a molecular probe targeting CAIX that can be labeled with 177Lu for the inhibition and localization of malignant gliomas. The uptake of [177Lu] Lu-XYIMSR-01 in U87MG tumors is 6.19 % of the injected dose per gram (% ID/g), and the tumor-to-muscle uptake ratio is 20.14. In the orthotopic glioma model, combined injection with Temozolomide (HY-17364) can significantly improve the survival rate of mice and inhibit tumor growth. DOTA-XYIMSR-01 shows promise for research in the field of anti-cancer therapy .

HY-P5297

DOTA-CXCR4-L	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA-CXCR4-L is a CXCR4 targeting peptide. DOTA-CXCR4-L can be used in the study of cancers, including glioblastoma and triple-negative breast cancer. NODAGA-LM3 can be labeled with [68Ga]/[177Lu] for the synthesis/research of Radionuclide-Drug Conjugates (RDCs) .

HY-P10444

DOTA Conjugated JM#21 derivative 7	Radionuclide-Drug Conjugates (RDCs) CXCR	Cancer
DOTA Conjugated JM#21 derivative 7 (compound Ligand-7) is a derivative of CXCR4 targeting peptide conjugated with DOTA and can be used to produce radioligands. Radiolabeled DOTA Conjugated JM#21 derivative 7, i.e., 177Lu-DOTA, has excellent CXCR4 tumor targeting. In vitro biodistribution results of 177Lu-DOTA showed very low uptake in all non-targeted organs except kidney . DOTA Conjugated JM#21 derivative 7 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P6825

PNT2001 LY4181530; PSMA-62	PSMA	Cancer
PNT2001 (LY4181530) is a potent prostate specific membrane antigen (PSMA) ligand with an IC₅₀ of 3.1 nM. PNT2001 can improve cellular internalization. 177Lu- and 225Ac-labeled PNT2001 can be used in prostate cancer research .

HY-137331

FAPI-46 1 Publications Verification	FAP	Cancer
FAPI-46 is a quinoline-based fibroblast activation protein (FAP)-targeted tracer. Use radioactivity FAPI-46 labeled with ⁶⁸Ga or ¹⁷⁷Lu can be used for tumor imaging in a variety of cancers and has higher tumor uptake rates and longer tumor accumulation .

HY-158266

DOTA-PSMA-EB-01 LNC1003	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
DOTA-PSMA-EB-01 (Compound LNC1003) is a specific inhibitor of PSMA (IC₅₀= 10.77 nM).DOTA-PSMA-EB-01 enhances the uptake and retention time of ¹⁷⁷Lu in tumors . DOTA-PSMA-EB-01 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-170779

DOTA-NI-FAPI-04	FAP	Cancer
DOTA-NI-FAPI-04 is a FAP inhibitor (IC₅₀ = 7.44 nM). By integrating FAP targeting with hypoxia-sensitive groups (nitroimidazole), DOTA-NI-FAPI-04 significantly enhances tumor uptake and retention capabilities. DOTA-NI-FAPI-04 chelates metallic isotopes (such as ⁶⁸Ga and ¹⁷⁷Lu) through DOTA to produce radioactive probes ([ ⁶⁸Ga]Ga/DOTA-NI-FAPI-04 and [ ¹⁷⁷Lu]Lu/DOTA-NI-FAPI-04), which can be used for research in tumor diagnostics and therapeutic agents. DOTA-NI-FAPI-04 holds dual targeting potential in the fields of cancer imaging, tumor microenvironment analysis, and radionuclide therapy, particularly suitable for scenarios where the tumor stroma and hypoxic regions synergistically interact .

HY-164725

FAPI-mFS	Radionuclide-Drug Conjugates (RDCs) FAP	Cancer
FAPI-mFS is an irreversible fibroblast activation protein (FAP) inhibitor, that enhances the uptake and retention time in cancer cells through its covalent binding property for FAP. FAPI-mFS can be used for cancer imaging the therapy, when labeled with radioactive 68Ga or 177Lu . FAPI-mFS can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P99239

Rosopatamab HUJ-591	PSMA Radionuclide-Drug Conjugates (RDCs)	Cancer
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 ( ¹⁷⁷Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency .

HY-P5126

DOTA-LM3 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 and 68 Ga-DOTA-LM3. 68 Ga-DOTA-LM3 shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-P10944

Unlabeled FXX489 NNS309	FAP	Cancer
Unlabeled FXX489 (NNS309) is a fibroblast activation protein (FAP)-targeting ligand. Unlabeled FXX489 can be labeled with ⁶⁸Ga and ¹⁷⁷Lu and shows anticancer effects. Unlabeled FXX489 can be used for the study of pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), breast cancer (BC), and colorectal cancer (CRC) .

HY-P5126A

DOTA-LM3 TFA 1 Publications Verification	Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor	Cancer
DOTA-LM3 TFA is a somatostatin receptor (SSTR) antagonist. LM3 refers to p-Cl-Phe- cyclo(D-Cys-Tyr-D-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)D-Tyr- NH2, as well as a somatostatin antagonist. DOTA-LM3 TFA is often isotopically labeled for tracing tumors in vivo, such as 177Lu-DOTA-LM3 TFA and 68 Ga-DOTA-LM3 TFA. 68 Ga-DOTA-LM3 TFA shows favorable biodistribution, high tumor uptake, good tumor retention, and few safety concerns. 177Lu-DOTA-LM3 TFA can be used for research in DOTATOC-negative liver metastases, such as pancreatic NET and extensive tumor thrombosis . DOTA-LM3 (TFA) can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-117410

Vipivotide tetraxetan Maximum Cited Publications 15 Publications Verification PSMA-617	Drug-Linker Conjugates for ADC	Cancer
Vipivotide tetraxetan (PSMA-617) is a high potent prostate-specific membrane antigen (PSMA) inhibitor, with a K_i of 0.37 nM. Vipivotide tetraxetan (PSMA-617) is designed consisting of three components: the pharmacophore Glutamate-urea-Lysine, the chelator DOTA able to complex both 68Ga or 177Lu, and a linker connecting these two entities. Glutamate-urea-Lysine is the selective pharmacophore to bind to prostate specific membrane antigen.

HY-P10743

BQ7876	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
BQ7876 is a probe targeting prostate-specific membrane antigen (PSMA) that contains a DOTA chelator. BQ7876, after being radiolabeled with radionuclide (177Lu), functions in both radionuclide imaging and tumor cell destruction by specifically binding to PSMA. BQ7876 shows potential for research in the field of metastatic castration-resistant prostate cancer (mCRPC) . BQ7876 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-106033

Edotreotide DOTATOC; SDZ-SMT 487; SMT 487	Radionuclide-Drug Conjugates (RDCs)	Cancer
Edotreotide is a ligand that selectively targets SSTR2 and can competitively bind to the receptor. Edotreotide mediates the targeted delivery, while modificated with radionuclides (such as ⁹⁰Y, ¹⁷⁷Lu, and ⁶⁸Ga) to SSTR-positive tumors and induces tumor cell apoptosis by releasing β rays. Edotreotide has strong tumor targeting and precise killing activity. Edotreotide is used in the synthesis of radionuclide-drug conjugates (RDCs) and is widely used in the field of neuroendocrine tumors (such as metastatic carcinoids, lung and thymus NETs) .

HY-P10781

PSMA-D5	Radionuclide-Drug Conjugates (RDCs) PSMA	Cancer
PSMA-D5 has a binding affinity for PSMA with K_i of 0.21 nM and can be used for PSMA tracing after radiolabeling. PSMA-D5 ([ ⁶⁸Ga]-labeled) contains a DOTA chelator, allowing convenient labeling with therapeutic radionuclides such as ¹⁷⁷Lu and ²²⁵Ac. PSMA-D5 ([ ⁶⁸Ga]-labeled) shows excellent pharmacokinetic properties, exhibiting remarkable tumor uptake in 22Rv1 tumors . PSMA-D5 can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs).

HY-100138

2-Aminoethyl-mono-amide-DOTA-tris(tBu ester)	Radionuclide-Drug Conjugates (RDCs) ADC Linker	Cancer
2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) is a metal chelator precursor containing a DOTA macrocyclic structure. DOTA can form highly stable complexes with metal ions (such as ⁶⁸Ga, ¹⁷⁷Lu) through four nitrogen atoms and four carboxylic acid groups to mediate targeted delivery of radionuclides. The tert-butyl ester group (tBu ester) of 2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) also protects the carboxylic acid group during synthesis, and forms a free carboxyl group after deprotection reaction for coupling with targeting molecules (such as antibodies, peptides). 2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) may be combined with tumor pre-targeting systems through bioorthogonal reactions (such as reverse electron demand Diels-Alder reaction) to study radioactive imaging or therapy of tumor tissues, and is mainly used in tumor pre-targeting research in the field of nuclear medicine .

Cat. No.	Product Name

HY-L177

Antibody Inhibitor Library	1,236 compounds
Antibody inhibitors are compounds with the same activity as the original therapeutic antibodies, which can be used as positive controls for drug efficacy evaluation and other studies. Antibody inhibitors can also assist in verifying the functional activity of the target protein. These antibody inhibitors are active in vivo and can achieve certain physiological functions by blocking or neutralizing target proteins, such as CD20, HER2, EGFR, VEGFR, TNF-α, etc. In drug screening, antibody inhibitor-based screening can be carried out to identify active compounds targeting target proteins and target diseases. MCE can provide 1,236 antibody inhibitors that can be used for drug development in cancer, immunity, infection and other hot research areas.

Antibody Inhibitor Library

1,236 compounds

Antibody inhibitors are compounds with the same activity as the original therapeutic antibodies, which can be used as positive controls for drug efficacy evaluation and other studies. Antibody inhibitors can also assist in verifying the functional activity of the target protein. These antibody inhibitors are active in vivo and can achieve certain physiological functions by blocking or neutralizing target proteins, such as CD20, HER2, EGFR, VEGFR, TNF-α, etc. In drug screening, antibody inhibitor-based screening can be carried out to identify active compounds targeting target proteins and target diseases.

MCE can provide 1,236 antibody inhibitors that can be used for drug development in cancer, immunity, infection and other hot research areas.

Cat. No.	Product Name	Type